NCT04498117

Who might be able to join this trial:

• You are 18 years old or older.
• You have been newly diagnosed with a specific type of ovarian, fallopian tube, or peritoneal cancer (called epithelial adenocarcinoma) that is at an advanced stage (Stage III or IV).
• Your cancer is one of these specific types: high grade serous, high grade endometrioid, undifferentiated, clear cell, mixed epithelial, or adenocarcinoma not otherwise specified (confirm with trial site).
• You have completed debulking surgery (an operation to remove as much of the tumor as possible), with most or all of the visible tumor removed, either before or after initial chemotherapy.
• You are in one of two groups: either you had surgery first and will start chemotherapy within 6 weeks of that surgery, or you had 3 rounds of chemotherapy first, then surgery, and will continue chemotherapy within 6 weeks after surgery.
• You have good enough veins to allow blood draws and intravenous treatments needed for the study.
• Your blood test for a cancer marker called CA-125 showed a level of 50 or higher before surgery or before starting chemotherapy.
• Your bone marrow is working well enough, based on blood test results showing healthy levels of infection-fighting cells and platelets (confirm with trial site for specific numbers).
• Your hemoglobin (a measure of healthy red blood cells) is at an acceptable level (a blood transfusion given at least 48 hours before your first treatment dose is allowed to help reach this level).
• Your liver is functioning well enough, based on blood test results (confirm with trial site for specific numbers).
• Your kidneys are functioning well enough, based on blood test results (confirm with trial site for specific numbers).
• You are generally well enough to carry out everyday activities with little or no limitation (referred to as an ECOG performance status of 0 or 1 — confirm with trial site).
• If you are able to become pregnant, you must be willing to use a highly effective form of birth control from your first treatment dose until 6 months after your last dose (in Belgium and South Korea, this must start 28 days before the first dose).
• You are willing and able to sign a consent form allowing the use of your health information for this study.
• You are willing and able to fill out quality-of-life questionnaires during the study.

Who may not be able to join:

• You have a known or recently tested BRCA1 or BRCA2 gene mutation result that is positive, unclear, or inconclusive within 28 days before starting treatment, especially if there are plans to use a type of drug called a PARP inhibitor as ongoing maintenance therapy after chemotherapy.
• You have a known genetic change in your tumor (called somatic HRD) and your doctors plan to use a PARP inhibitor as maintenance therapy after chemotherapy.
• Your cancer is of a specific type not included in this trial, such as mucinous, carcinosarcoma, tumors with neuroendocrine features, or low-grade adenocarcinoma.
• You are currently breastfeeding or have a positive pregnancy test within 7 days before your first dose.
• You have a serious medical or mental health condition that, in your doctor's opinion, could prevent you from completing the treatment as planned.
• You have an active autoimmune disease (such as rheumatoid arthritis, lupus, ulcerative colitis, Crohn's disease, multiple sclerosis, or ankylosing spondylitis) that currently requires active treatment.
• You have a known allergy to mouse-derived proteins or to any of the ingredients in the study drug (oregovomab), paclitaxel, or carboplatin.
• You are currently taking long-term immune-suppressing drugs such as cyclosporine (confirm with trial site for full list).
• You have been taking steroid medications (like prednisone) on an ongoing basis for more than 5 days, unless it is via an inhaler or part of a planned tapering schedule (steroid premedication as standard care before chemotherapy is allowed).
• You have a known condition that weakens your immune system, whether inherited, present from birth, or developed over time.
• You have a significant active infection at the time of screening.
• You have HIV and are not on effective treatment with an un